Retrospective Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Aug 7, 2017; 23(29): 5379-5385
Published online Aug 7, 2017. doi: 10.3748/wjg.v23.i29.5379
Table 1 Characteristics of the patients with and without hepatocellular carcinoma
HCC (+)HCC (-)P vaule
n3229
Age71.0 ± 11.261.8 ± 11.30.0064
Sex (M/F)19/1317/120.9523
Decreased BW (kg)1.68 ± 3.813.43 ± 3.000.0130
Decreased BW (%)2.56 ± 5.235.36 ± 4.270.0127
TLV (3.75/7.5/15 mg/d)3/24/52/22/50.9325
Furosemide (≤ 20/20 <, ≤ 40/> 40 mg/d)8/13/118/11/100.9671
Spironolactone (≤ 25/25 <, ≤ 50/> 50 mg/d)2/8/222/10/170.6986
Portal thrombus (+/-)8/240/290.0039
Albumin (g/dL)2.64 ± 0.382.31 ± 0.480.0045
CPT score10.7 ± 2.011.1 ± 1.70.2357
BUN (mg/dL)21.3 ± 8.218.6 ± 10.20.1584
Na (mEq/L)134.1 ± 5.7134.6 ± 5.40.5620
K (mEq/L)4.02 ± 0.673.85 ± 0.550.4827
eGFR (mL/min)58.66 ± 21.7869.52 ± 40.390.8285
LDH (IU/L)293.8 ± 164.1259.6 ± 107.20.4228
Platelet count (× 104/μL)10.87 ± 5.3812.40 ± 11.350.8852
T factor of TNM classification (T1/T2/T3a and T3b)6/13/13--